PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

计划入组 135 人 · 首次发布于 2022 年 12 月 6 日

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

计划入组 6 人 · 首次发布于 2024 年 11 月 12 日

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

计划入组 42 人 · 首次发布于 2024 年 8 月 19 日

Correction of Q347X mutation(Beam Therapeutics)

KRAS mutation G12D-targeted ONCOlogues ( Oncogenuity)

Personalized Mutation-derived Tumor Vaccine(NovoCure)

Cogent Biosciences

United States

Nuvation Bio

United States

FONDS DE DOTATION HTC PROJECT

France

Prelude Therapeutics' PRT3789 Shows Promise in SMARCA4-Mutated Cancers

Novel Synthetic Lethal Approaches Show Promise in Targeting MTAP and SMARCA4 Mutations in Lung Cancer

Foghorn Therapeutics Advances Oncology Programs Targeting Chromatin Dysregulation